Street View: Thermo Fisher's 2026 forecast cautious but consistent

Thermo Fisher Scientific TMO.N on Thursday forecast annual profit below Wall Street estimates, expecting pressure from cuts to U.S. academic research to spill into 2026

29 analysts rate the stock "buy" on average; median PT is $665 - data compiled by LSEG

LIGHTS A SMALL SPARK

J.P. Morgan ("overweight," PT: $710) says TMO's 2026 guidance aligns with the messaging it has maintained since laying out its two‑year financial framework in July, and believes co pointing to the low end reflects typical management conservatism amid recent market volatility

Raymond James ("outperform," PT: $670) says numbers will rise, with performance helping ‘retire risk as the year goes on,’ as management noted, and also acknowledges some frustration that TMO is starting yet another year with its outlook taking a hit, even if this year’s reset is smaller

TD Cowen ("buy," PT: $683) says 1Q has unique factors, and the ’26 guide is in line, though consensus was slightly ahead, and co's ongoing improvement in Biopharma demand isn’t reflected in forecasts, giving estimates a strong bias to the upside

Jefferies says solid beats are welcome, but upward estimate revisions are still lacking; FY26 guidance was as expected and conservative, but the soft 1Q starting point limits near‑term expectations